Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
Lyon (France), March 26, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris:…
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcytes 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
March 18, 2026 19:34 ET | Source: Vaxcyte, Inc. Based on the…
Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement
The agreement enables a full tech transfer of the chikungunya vaccine for…
Valneva Provides Update on Chikungunya Vaccine IXCHIQ
Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of…
Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or…
React19 Launches This Is Our Shot Campaign as U.S. Vaccine Injury Victims Continue to Go Unheard and Uncompensated
SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- As the federal…
BlueWillow Biologics Intranasal Bird Flu Vaccine Shows Signs of Broad Immune Response in Phase I Clinical Trial Published in Nature Communications
ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- BlueWillow Biologics, Inc.,…
Award-Winning Film An Inconvenient Study Sparks Global Debate on Vaccine Safety and Chronic Disease
AUSTIN, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The award-winning film An Inconvenient…
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against…
Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With Partners Including European Vaccine Initiative, University of Copenhagen, and University of Tbingen
TOKYO, July 17, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT)…
